Therapy Areas: Inflammatory Diseases
Amgen acquires ChemoCentryx
21 October 2022 -

Amgen (NASDAQ:AMGN), a United States-based biopharmaceutical company, announced on Thursday that it has completed its acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company.

The transaction is valued at USD52 per share in cash, representing aggregate merger consideration of around USD3.7bn.

The deal includes TAVNEOS, an orally administered selective complement 5a receptor inhibitor that received approval from the US Food and Drug Administration as an adjunctive therapy for adults with severe active ANCA-associated vasculitis in addition to standard of care that includes glucocorticoids and either rituximab or cyclophosphamide immunosuppressant therapy. It also adds three early-stage drug candidates that are aimed at chemoattractant receptors and other inflammatory diseases and an oral checkpoint for cancer.

Login
Username:

Password: